MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis
Status:
Terminated
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Patients with end stage renal disease (ESRD) who use peritoneal dialyses with Physioneal(R)
(Baxter A/S, Denmark) were allocated to inject either placebo or tinzaparin daily into the
morning dialysis bag. Active medication, as well as placebo, was added for three months
separated by a one month washout period. At the beginning and end of each treatment period
peritoneal equilibrations tests (PE-tests), Kt/V, blood and dialysate samples were analyzed.
We, the researchers at Ribe County Hospital, set out to examine inflammation (local and
systemic), nutrition and ultrafiltration.